Benjamin L. Oakes Co-founder, president and CEO of Scribe Therapeutics, a molecular engineering company developing CRISPR-based genetic medicines. He previously conducted genome-editing research in Jennifer Doudna's and David Savage's labs at UC Berkeley.
Benjamin L. Oakes Co-founder, president and CEO of Scribe Therapeutics, a molecular engineering company developing CRISPR-based genetic medicines. He previously conducted genome-editing research in Jennifer Doudna's and David Savage's labs at UC Berkeley.
Career
CEO at Scribe Therapeutics from 2018 to PresentLeads Scribe's development of engineered CRISPR-based genetic medicines.